A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 12 Dec 2023
At a glance
- Drugs LUNA 18 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 08 Sep 2021 Planned initiation date (Estimated date of first participant enrollement) changed from 31 Aug 2021 to 30 Sep 2021.
- 08 Sep 2021 Status changed from not yet recruiting to recruiting.
- 26 Aug 2021 New trial record